Trial Profile
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic; Registrational
- Sponsors Eisai Inc
- 15 Aug 2023 Primary endpoints have been amended in the study protocol.
- 15 Aug 2023 Planned End Date changed from 30 Sep 2022 to 31 Dec 2023.
- 16 Sep 2020 Planned primary completion date changed from 8 Aug 2020 to 8 Aug 2021.